Nflection Therapeutics
2 known investors
NFlection is a clinical-stage biopharmaceutical company developing topical first-in-class MEK inhibitors for RAS-mediated disorders. Its therapies target patients with neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks such as keratinocytic epidermal nevi and nevi sebacei.
BiotechMedical Devices
Investors · 2
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $299.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Nflection Therapeutics do?
- NFlection is a clinical-stage biopharmaceutical company developing topical first-in-class MEK inhibitors for RAS-mediated disorders. Its therapies target patients with neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks such as keratinocytic epidermal nevi and nevi sebacei.
- Who are Nflection Therapeutics's investors?
- Nflection Therapeutics's investors include F-Prime Capital Partners, venBio Partners.